急性骨髄性白血病(AML)治療薬の世界市場2015-2019

◆英語タイトル:Global Acute Myeloid Leukemia Therapeutics Market 2015-2019
◆商品コード:IRTNTR4899
◆発行会社(リサーチ会社):Technavio
◆発行日:2014年12月24日
◆ページ数:88
◆レポート言語:英語
◆レポート形式:pdf
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥260,000見積依頼/購入/質問フォーム
Five UserUSD2,800 ⇒換算¥291,200見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD3,500 ⇒換算¥364,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、急性骨髄性白血病(AML)治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、急性骨髄性白血病(AML)治療薬の世界市場規模及び予測、市場シェア、地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。
【レポートの概要】

About Acute Myeloid Leukemia
Acute myeloid leukemia, also known as acute myelogenous leukemia, is a hematopoietic disorder that starts either in hematopoietic stem cells or lineage-specific progenitor cells. Neoplasms arise from bone marrow, however, it spreads quickly into the blood. In the later stages of the disorder, it spreads to spleen, lymph node, liver, brain, spinal cord and testicles. Clonal expansion of the myeloid blasts and the loss of normal hematopoiesis are the main characteristic of acute myeloid leukemia. The disease affects the elderly people with age of 67 years. Fever, pallor, fatigue and hemorrhages are some of the clinical symptoms of the disease. Smoking, exposure to certain chemicals such as benzene, exposure to radiations, cancer patients, who are treated with chemotherapy, blood disorder or genetic mutations are some of the risk factors for the development of acute myeloid leukemia in patients.

TechNavio’s analysts forecast the Global Acute Myeloid Leukemia Therapeutics market to grow at a CAGR of 19.75 percent over the period 2014-2019.

[Covered in this Report]
This report covers the present scenario and the growth prospects of the Global Acute Myeloid Leukemia Therapeutics market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic, off-label and branded therapies used for treatment.
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Acute Myeloid Leukemia Therapeutics market. In addition, the report discusses the major drivers that influence the growth of the market and also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio’s report, Global Acute Myeloid Leukemia Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the APAC regions and the EMEA regions; it also covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key Regions]
• Americas
• APAC
• EMEA

[Key Vendors]
• Bristol Myers Squibb
• Celgene
• Johnson & Johnson
• Pfizer

[Other Prominent Vendors]
• Abbott
• Ambit BioSciences
• Amgen
• Astex Pharmaceuticals
• AstraZeneca
• Baxter Healthcare
• Bayer
• Boehringer Ingelheim
• Celator Pharmaceuticals
• Chroma Therapeutics
• Chugai Pharmaceutical
• CTI Biopharma
• Cyclacel Pharmaceuticals
• Eisai
• F. Hoffmann-La Roche
• Immune Pharmaceuticals
• Innate Pharma
• Kanisa Pharmaceuticals
• Meda
• Merck Sharp & Dohme
• Midas Pharmaceuticals
• Neovii Biotech
• Nippon Shinyaku
• Novo Nordisk
• Sanofi
• Sunesis Pharmaceuticals
• Teva Pharmaceutical
• Tolero Pharmaceuticals

[Market Driver]
• Unmet Needs in the Market
• For a full, detailed list, view our report

[Market Challenge]
• Expensive Treatment
• For a full, detailed list, view our report

[Market Trend]
• Expected Entry of Novel Therapies
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【レポートの目次】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04.Product Profiles
04.1.1 Cytoxan
04.1.2 Vidaza
04.1.3 Dacogen
04.1.4 Idamycin PFS

05.Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology

06.Introduction

07.Disease Overview
07.1 Understanding the Disease
07.2 Etiology and Risk Factors
07.3 Pathophysiology
07.4 Epidemiology
07.5 Classification
07.5.1 FAB Classification
07.5.2 WHO Classification
07.6 Diagnosis
07.6.1 Blood Samples
07.6.2 Bone Marrow Samples
07.6.3 Spinal Fluid
07.6.4 CBC and Peripheral Smear
07.6.5 Blood Chemistry and Coagulation Tests
07.6.6 Microscopic Exams
07.6.7 Cytochemistry
07.6.8 Flow Cytometry and Immunohistochemistry
07.6.9 Cytogenetics
07.6.10 FISH and PCR
07.6.11 X-Ray
07.6.12 CT Scan
07.6.13 Ultrasound
07.6.14 MRI Scan
07.7 Treatment and Management
07.7.1 Induction Therapy
07.7.2 Post Remission Therapy
07.8 Economic Burden

08.Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 Five Forces Analysis

09.Market Segmentation by Class of Drugs
09.1 Alkylating Agent
09.2 Cytotoxic Antibiotic
09.3 Topoisomerase Inhibitor
09.4 Others

10.Geographical Segmentation

11.Buying Criteria

12.Market Growth Drivers

13.Drivers and their Impact

14.Market Challenges

15.Impact of Drivers and Challenges

16.Market Trends

17.Trends and their Impact

18.Pipeline Portfolio

19.Vendor Landscape
19.1 Competitive Scenario
19.1.1 Key News
19.1.2 Mergers and Acquisitions
19.2 Market Share Analysis 2014
19.2.1 Celgene
19.2.2 Johnson & Johnson
19.2.3 Pfizer
19.2.4 Bristol Myers Squibb
19.3 Other and Future Prominent Vendors

20.Key Vendor Analysis
20.1 Bristol Myers Squibb
20.1.1 Key Facts
20.1.2 Business Description
20.1.3 Business Segmentation
20.1.4 Revenue by Business Segmentation
20.1.5 Revenue Comparison 2013 and 2014
20.1.6 Sales by Geography
20.1.7 Business Strategy
20.1.8 Key Developments
20.1.9 SWOT Analysis
20.2 Celgene
20.2.1 Key Facts
20.2.2 Business Description
20.2.3 Business Segmentation
20.2.4 Revenue by Business Segmentation
20.2.5 Revenue Comparison 2013 and 2014
20.2.6 Sales by Geography
20.2.7 Business Strategy
20.2.8 Key Developments
20.2.9 SWOT Analysis
20.3 Johnson and Johnson
20.3.1 Key Facts
20.3.2 Business Description
20.3.3 Business Segmentation
20.3.4 Revenue by Business Segmentation
20.3.5 Revenue Comparison 2013 and 2014
20.3.6 Sales by Geography
20.3.7 Business Strategy
20.3.8 Key Developments
20.3.9 SWOT Analysis
20.4 Pfizer
20.4.1 Key Facts
20.4.2 Business Description
20.4.3 Business Segmentation
20.4.4 Revenue by Business Segmentation
20.4.5 Revenue Comparison 2013 and 2014
20.4.6 Sales by Geography
20.4.7 Business Strategy
20.4.8 Key Developments
20.4.9 SWOT Analysis

23.Other Reports in this Series

[List of Exhibits]
Exhibit 1: Market Research Methodology
Exhibit 2: Snapshot of Acute Myeloid Leukemia
Exhibit 3: Percentage of Acute Myeloid Leukemia Cases in Comparison with Other Types of Leukemia in the US 2014
Exhibit 4: FAB Classification of Acute Myeloid Leukemia
Exhibit 5: FAB Classification of Acute Myeloid Leukemia and the Percentage of Patients in Each Class
Exhibit 6: Percentage Distribution of Acute Myeloid Leukemia Patients According to the FAB Classification
Exhibit 7: The WHO Classification of Acute Myeloid Leukemia
Exhibit 8: Treatment Options for Acute Myeloid Leukemia
Exhibit 9: Treatment Options for Relapsed Acute Myeloid Leukemia
Exhibit 10: Snapshot of the Economic Burden of Acute Myeloid Leukemia
Exhibit 11: Cost Per Patient in Different Treatment Cycles in the US (2012)
Exhibit 12: Cost Per Patient in Different Treatment Cycles in the UK (2012)
Exhibit 13: Snapshot of the Global Acute Myeloid Leukemia Therapeutics Market, 2014
Exhibit 14: Global Acute Myeloid Leukemia Therapeutics Market 2014-2019 (US$ million)
Exhibit 15: Global Acute Myeloid Leukemia Therapeutics Market Segmentation by Class of Drugs
Exhibit 16: Global Acute Myeloid Leukemia Therapeutics Market Segmentation by Class of Drugs 2014
Exhibit 17: Global Acute Myeloid Leukemia Therapeutics Market by Geographical Segmentation 2014
Exhibit 18: Buying Criteria of Global Acute Myeloid Leukemia Therapeutics Market
Exhibit 19: Phase III Pipeline Molecules for Acute Myeloid Leukemia
Exhibit 20: Global Acute Myeloid Leukemia Therapeutics Market Share Analysis 2014
Exhibit 21: Authorization Details of Vidaza
Exhibit 22: Regulatory History of Dacogen
Exhibit 23: Authorization Details of Dacogen
Exhibit 24: Bristol-Myers Squibb: Business Segmentation 2014
Exhibit 25: Bristol-Myers Squibb: Business Segmentation by Revenue 2013 and 2014 (US$ million)
Exhibit 26: Bristol-Myers Squibb: Sales by Geography (in US$ million)
Exhibit 27: Celgene: Business Segmentation by Revenue 2013 and 2014
Exhibit 28: Celgene: Sales by Geography 2014 (Pharmaceuticals Division)
Exhibit 29: Celgene: Sales by Geography 2014 (Diagnostics Division)
Exhibit 30: Johnson & Johnson: Business Segmentation by Revenue 2014
Exhibit 31: Johnson & Johnson: Business Segmentation by Revenue 2013 and 2014 (US$ million)
Exhibit 32: Johnson & Johnson: Sales by Geography 2014
Exhibit 33: Pfizer: Business Segmentation
Exhibit 19: Pfizer: Revenue by Business Segmentation 2014
Exhibit 20: Pfizer: Revenue by Business Segmentation 2013 and 2014 (US$ million)
Exhibit 21: Pfizer: Revenue by Geographical Segmentation 2014



【掲載企業】

Bristol Myers Squibb , Celgene , Johnson & Johnson, Pfizer , Abbott, Ambit BioSciences, Amgen, Astex Pharmaceuticals, AstraZeneca, Baxter Healthcare, Bayer, Boehringer Ingelheim, Celator Pharmaceuticals, Chroma Therapeutics, Chugai Pharmaceutical, CTIBiopharma, Cyclacel Pharmaceuticals, Eisai, F. Hoffmann-La Roche, Immune Pharmaceuticals, Innate Pharma, Kanisa Pharmaceuticals, Meda , Merck Sharp & Dohme, Midas Pharmaceuticals, Neovii Biotech, Nippon Shinyaku , Novo Nordisk, Sanofi, SunesisPharmaceuticals, Teva Pharmaceutical, Tolero Pharmaceuticals

【レポートのキーワード】

急性骨髄性白血病(AML)治療薬、製薬、医薬品、アルキル化薬、抗悪性腫瘍性抗生物質、トポイソメラーゼ阻害剤

【リサーチ方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[急性骨髄性白血病(AML)治療薬の世界市場2015-2019]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆